San Diego, CA, United States of America

John Lloyd Tucker

This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Neurocrine Biosciences, Inc.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: John Lloyd Tucker - Innovator in Neurocrine Biosciences

Introduction

John Lloyd Tucker is an accomplished inventor based in San Diego, CA. He currently works at Neurocrine Biosciences, Inc., where he contributes to the development of innovative treatments for various medical conditions. Although he has not yet been granted any patents, his work is focused on significant advancements in the field of pharmacology.

Latest Patent Applications

John Lloyd Tucker has submitted several notable patent applications. One of his latest applications is titled "Processes for the Synthesis of Valbenazine." This application relates to processes for preparing a specific compound that acts as an inhibitor of vesicular monoamine transporter 2 (VMAT2), which is useful in treating hyperkinetic movement disorders such as tardive dyskinesia (TD). Another significant application is "CRF Receptor Antagonists and Methods of Use." This application provides compounds that antagonize corticotropin-releasing factor (CRF) receptors, particularly CRF receptor 1, along with related preparations and methods for treating diseases like congenital adrenal hyperplasia (CAH).

Conclusion

John Lloyd Tucker is a dedicated inventor whose work at Neurocrine Biosciences, Inc. focuses on developing innovative solutions for complex medical challenges. His latest patent applications reflect his commitment to advancing healthcare through scientific research and innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…